<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Some examples of M2e-based vaccines</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Carrier</th>
    <th>Animals</th>
    <th>Immunization route*</th>
    <th>Main results</th>
    <th>Reference</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="2">Hepatitis B virus core protein</td>
    <td>Mice</td>
    <td>IP
     <sup>+</sup> or IN
    </td>
    <td>3 immunizations at 3-week intervals with 5, 10, or 50 μg led to the formation of M2e-antibodies in mice. Groups immunized with 10 μg IP and IN in subsequent vaccination studies were protected after challenge with 5 LD
     <sub>50</sub> of A/PR/8/34 (H1N1) and A/Victoria/3/75 (H3N2). The significant role of M2e antibodies in passive transfer experiments was shown.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR88">88</xref>]
    </td>
   </tr>
   <tr>
    <td>Mice</td>
    <td>IM
     <sup>+</sup>
    </td>
    <td>3 immunizations at 2-week intervals with 50 μg induced high levels of M2e-antibodies. Challenge with 5 LD
     <sub>50</sub> of different heterologous viruses showed high degree of protection.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR122">122</xref>]
    </td>
   </tr>
   <tr>
    <td>Modified form of the leucine zipper of the yeast transcription factor GCN4</td>
    <td>Mice</td>
    <td>IP
     <sup>+</sup> or IN
     <sup>+</sup>
    </td>
    <td>3 immunizations with 10 μg doses led to the formation of specific IgG1 and IgG2a M2e antibodies. The tetrameric M2e-tGCN4 vaccine induced M2e-specific IgG antibody that recognized natural M2 ectodomain. Immunized mice were fully protected against challenge with 4 LD
     <sub>50</sub> X47.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR17">17</xref>]
    </td>
   </tr>
   <tr>
    <td>Prime with M2-DNA and boost with recombinant adenovirus expressing M2</td>
    <td>Mice</td>
    <td>IM</td>
    <td>2 immunizations (50 μg each) led to the enhanced antibody response. Challenge with LD
     <sub>50</sub> of A/PR/8/34 (H1N1) and 10 LD
     <sub>50</sub> of A/FM/1/47-MA (H1N1) and LD
     <sub>50</sub> A/Thailand/SP-83/2004 (H5N1) showed the significant cross-protection of the vaccine. The important protective role of CD4 + and CD8 + cells was also shown.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR119">119</xref>]
    </td>
   </tr>
   <tr>
    <td>T7 bacteriophage nanoparticles</td>
    <td>Mice</td>
    <td>SC
     <sup>+</sup>
    </td>
    <td>3 immunizations (10
     <sup>9</sup> PFU each) led to the formation of IgG1 and IgG2a M2e-antibodies, as well as a T-cell response. Challenge with 4 LD
     <sub>50</sub> of A/PR/8/34 (H1N1) and X47 showed a high degree of protection.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR38">38</xref>]
    </td>
   </tr>
   <tr>
    <td>Rotavirus fragment NSP4
     <sub>98–135</sub>
    </td>
    <td>Mice</td>
    <td>SC
     <sup>+</sup>
    </td>
    <td>3 immunizations (10 μg each) with a chimeric protein resulted in the formation of an increased level of antibodies compared with immunization with M2e peptides. The formation of IgG1 M2e antibodies and to a lesser extent IgG2a was induced. Challenge using 3 LD
     <sub>50</sub> of A/PR/8/34 (H1N1) or A/equine/London/72 (H7N7) did not reveal significant differences between the chimeric and peptide vaccine, however lung virus titers 3 d.p.i. were significantly lower in the M2e-NSP4 group.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR3">3</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="3">Keyhole limpet hemocyanin (KLH) or 
     <italic>Neisseria meningitides</italic> outer membrane protein complex (OMPC)
    </td>
    <td>Mice</td>
    <td>SC or IM
     <sup>+</sup>
    </td>
    <td>3 immunizations (20 μg each) at 4-week intervals led to the formation of high levels of antibodies with cross-reactivity. Challenge with LD
     <sub>90</sub> of A/Hong Kong/68xPR8 reassortant resulted in complete survival and lower weight loss in vaccinated mice compared with controls.
    </td>
    <td valign="middle" rowspan="3">[
     <xref ref-type="bibr" rid="CR28">28</xref>]
    </td>
   </tr>
   <tr>
    <td>Ferrets</td>
    <td>IM
     <sup>+</sup>
    </td>
    <td>3 immunizations (100 μg each) at 4-week intervals showed that the OMPC-based vaccine was more immunogenic than the KHL-based vaccine. Challenge with 100 TCID
     <sub>50</sub> A/PR/8/34 (H1N1) revealed significantly lower replication of the challenge virus in the nasal turbinates and lungs.
    </td>
   </tr>
   <tr>
    <td>Rhesus monkeys</td>
    <td>IM
     <sup>+</sup>
    </td>
    <td>3 immunizations (10 μg each) during 25 weeks (immunization on 0, 8, and 25 weeks) with an OMPC-based vaccine led to the formation of an increased level of M2e antibodies. Sera were examined after challenge with A/Hong Kong/68xPR8 after passive transfer immunization of mice, and protective efficacy was shown.</td>
   </tr>
   <tr>
    <td>
     <italic>Brucella abortus</italic> lumazine synthase protein (BLS)
    </td>
    <td>Mice</td>
    <td>SC, SC
     <sup>+</sup>, IM, IM
     <sup>+</sup>, IN, IN
     <sup>+</sup>
    </td>
    <td>3 immunizations (10 μg each) using various routes at 3-week intervals led to the formation of IgG1 and IgG2a M2e-antibodies in different ratios. SC+ immunization produced the highest level of antibodies and was chosen for further study. Challenge with 5 LD
     <sub>50</sub> of A/PR/8/34 (H1N1) showed the protective efficacy of the vaccine.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR2">2</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2">Malva mosaic virus nanoparticles</td>
    <td>Mice</td>
    <td>SC
     <sup>+</sup>
    </td>
    <td>2 immunizations (20 μg each) at a 2-week interval led to the formation of IgG1 and IgG2a M2e-antibodies, whereas immunization with M2e peptides was not immunogenic. Significantly lower replication of the challenge virus in nasal turbinates and lungs was shown after challenge with A/WSN/1933 (H1N1).</td>
    <td valign="middle" rowspan="2">[
     <xref ref-type="bibr" rid="CR70">70</xref>]
    </td>
   </tr>
   <tr>
    <td>Dogs</td>
    <td>IM
     <sup>+</sup>
    </td>
    <td>3 immunizations (80 μg each) at 3-week intervals led to the formation of cross-reactive M2e-antibodies and revealed the need for adjuvant. Challenge was not performed.</td>
   </tr>
   <tr>
    <td>H1N1 HA DNA</td>
    <td>Mice</td>
    <td>IM
     <sup>+</sup>
    </td>
    <td>2 immunizations (0.2 μg each) at a 3-week interval led to the formation of cross-reactive M2e-antibodies. High protection of immunized mice was shown against challenge with 5 LD
     <sub>50</sub> of A/Aquatic Bird/Korea/W81/2005. In addition, HA-specific CD8+ and M2e-specific T cell responses were elicited
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR92">92</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="3">
     <italic>Salmonella typhimurium</italic> flagellin
    </td>
    <td>Mice</td>
    <td>SC</td>
    <td>3 immunizations (6 μg each) at 3-week intervals led to the formation of a high level of M2e-antibodies. Full protection of vaccinated mice was shown against challenge with 10 LD
     <sub>50</sub> of A/Aichi/2/68 (H3N2).
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR113">113</xref>]
    </td>
   </tr>
   <tr>
    <td>Mice</td>
    <td>SC or IN</td>
    <td>2 immunizations (3 μg each) at a 2-week interval led to the formation of a higher rate of M2e-antibodies than immunization with M2e-peptides. There was no decline in the following 10 months. High protection of immunized mice was shown against challenge with LD
     <sub>90</sub> of A/PR/8/34 (H1N1).
    </td>
    <td valign="middle" rowspan="2">[
     <xref ref-type="bibr" rid="CR46">46</xref>]
    </td>
   </tr>
   <tr>
    <td>Rabbits</td>
    <td>IM</td>
    <td>2 immunizations (15 μg each) at a 3-week interval led to the formation of M2e-antibodies.</td>
   </tr>
   <tr>
    <td>Multiple antigenic peptide</td>
    <td>Mice</td>
    <td>SC
     <sup>+</sup>
    </td>
    <td>Single immunization led to the formation of high levels of M2e antibodies, which insignificantly declined in the following 6 months. 2 immunizations led to significant clearance of virus 3 days after challenge with 10 LD
     <sub>50</sub> A/Beijing/501/09 and protected against weight loss.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR141">141</xref>]
    </td>
   </tr>
   <tr>
    <td>DNA expressing fusion M2e-NP protein</td>
    <td>Pigs</td>
    <td>SC
     <sup>+</sup>
    </td>
    <td>3 immunizations (200 μg each) at 3-week intervals did not protect animals after challenge with 10
     <sup>8</sup> TCID
     <sub>50</sub> of A/Sw/Best/96 (H1N1) but led to more serious signs of disease compared with the control group.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR41">41</xref>]
    </td>
   </tr>
   <tr>
    <td>Lipopeptides</td>
    <td>Mice</td>
    <td>SC</td>
    <td>2 immunizations (20 nmol each) at a 2-week interval with shortened form of M2e (a.a. 2–16) led to the same level of M2e antibody production as immunization with full-length M2e (a.a. 2–24), and led to lower viral titers in lungs and nasal turbinates after challenge with 10
     <sup>4.5</sup> PFU of A/Memphis/1/71xA/Bellamy/42 (H3N1) virus.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR94">94</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2">Keyhole limpet haemocyanin (KLH with full length M2e (M2e-KLH) and M2e
     <sub>2–10</sub> (SP1-KHL)
    </td>
    <td>Mice</td>
    <td>IP
     <sup>+</sup>
    </td>
    <td>3 immunizations at 3-week intervals led to the formation of M2e-antibodies for both vaccines. Vaccinated groups were more protected than the control group against challenge with 4 LD
     <sub>50</sub> of A/PR/8/34 (H1N1). M2e-KLH was more immunogenic and protective than SP1-KHL.
    </td>
    <td valign="middle" rowspan="2">[
     <xref ref-type="bibr" rid="CR18">18</xref>]
    </td>
   </tr>
   <tr>
    <td>Rabbits</td>
    <td>n/m</td>
    <td>3 immunizations at 3-week intervals showed greater immunogenicity of SP1-KHL. Serum from immunized rabbits provided protection in a mice passive transfer study against challenge with 4 LD
     <sub>50</sub> of A/PR/8/34 (H1N1). SP1-KHL was also more immunogenic in outbred New Zealand white rabbits than in inbred BALB/c mice.
    </td>
   </tr>
   <tr>
    <td>VLP</td>
    <td>Mice</td>
    <td>IM</td>
    <td>2 immunizations at a 4-week interval led to the formation of M2e-antibodies, and protected mice against challenge with 4 LD
     <sub>50</sub> of A/Philippines/2/82(H3N2) 4 weeks and 8 months after boost.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR58">58</xref>]
    </td>
   </tr>
   <tr>
    <td>M13 phage</td>
    <td>SPF chickens</td>
    <td>IM
     <sup>+</sup> (1st), IM (2nd)
    </td>
    <td>2 immunizations with the hybrid phage expressing shortened form of M2e (a.a. 2–9) at a dose of 1 × 10
     <sup>10</sup> phage/200 μL produced specific antibodies against M2e (2–9) in broiler chickens.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR80">80</xref>]
    </td>
   </tr>
   <tr>
    <td>CTA1-DD</td>
    <td>Mice</td>
    <td>IN</td>
    <td>2 immunizations at 3-week intervals induced strong M2e-specific serum antibody response and stimulated significant anti-M2e IgA antibody titers in bronchial lavage. Vaccination provided strong protective immunity against challenge with 4 LD
     <sub>50</sub> of X47 virus.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR25">25</xref>]
    </td>
   </tr>
   <tr>
    <td>8C6 and 1B12 antibodies (recognize M2e
     <sub>6–13</sub>)
    </td>
    <td>Mice</td>
    <td>IP (passive transfer)</td>
    <td>Passive transfer with 8C6 and 1B12 led to the formation of a high level of M2e antibodies and 75% protection of vaccinated mice against challenge with 5 LD
     <sub>50</sub> of A/PR/8/34 (H1N1), compared with 0% protection in control group.
    </td>
    <td>[
     <xref ref-type="bibr" rid="CR78">78</xref>]
    </td>
   </tr>
   <tr>
    <td>M2e-specific IgG2a MAb65</td>
    <td>Mice</td>
    <td>IP (passive transfer)</td>
    <td>Passive immunization reduced transmission of A/Udorn/72 (H3N2) and A/Hong Kong/68 (H3N2) challenge viruses and led to lower viral titer in lungs and nasal turbinates.</td>
    <td>[
     <xref ref-type="bibr" rid="CR60">60</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>* IP, intraperitoneal: IN, intranasal; SC, subcutaneous; IM, intramuscular; n/m, not mentioned; 
   <sup>+</sup>, with adjuvant
  </p>
 </table-wrap-foot>
</table-wrap>
